Trimel Announces Voting Results For 2014 Annual General And Special Shareholders' Meeting
June 12, 2014

Toronto, Canada, June 12, 2014 - Trimel Pharmaceuticals Corporation (TSX: TRL) today announced the voting results from its annual general and special meeting held on June 12, 2014.  The total number of shares represented in person or by proxy at the meeting was 121,019,361, representing 74.19% of Trimel's total issued and outstanding shares. 

Shareholders voted in favour of the reappointment of the auditors of the company, in favour of ratifying the amended and restated by-laws of the company and voted as follows in connection with the election of the directors of the company:

Name

Votes For (%)

Votes Withheld (%)

Ian Ihnatowycz

83,341,992 (69.43%)

36,695,676 (30.57%)

John Friedrichsen

120,019,043 (99.99%)

18,625 (0.01%)

Stephen Gregory

119,926,872 (99.91%)

110,796 (0.09%)

Matthew Pfeffer

83,323,600 (69.41%)

36,714,068 (30.59%)

Rolf Reininghaus

119,358,688 (99.43%)

678,980 (0.57%)

Tom Rossi

79,224,277 (66.00%)

40,813,391 (34.00%)

Jeffrey Sherman

78,541,818 (67.69%)

37,495,850 (32.31%)

Dr. D. Lorne Tyrrell

120,006,599 (99.98%)

31,069 (0.02%)


For further information regarding Trimel Pharmaceuticals Corporation, please contact Kenneth Howling, Chief Financial Officer at (416) 679-0536 or Trimel via email at ir@trimelpharmaceuticals.com.

About Trimel

Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders.  Natesto™, a product utilizing Trimel's licensed bioadhesive nasal gel technology, has been approved for sale in the United States by the FDA.www.trimelpharmaceuticals.com. 

distributed by